Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) EPS (Basic) (2020 - 2025)

Historic EPS (Basic) for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q3 2025 value amounting to -$0.36.

  • Barinthus Biotherapeutics' EPS (Basic) fell 7142.86% to -$0.36 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.88, marking a year-over-year decrease of 2617.45%. This contributed to the annual value of -$1.55 for FY2024, which is 1859.11% up from last year.
  • Latest data reveals that Barinthus Biotherapeutics reported EPS (Basic) of -$0.36 as of Q3 2025, which was down 7142.86% from -$0.52 recorded in Q2 2025.
  • Barinthus Biotherapeutics' EPS (Basic)'s 5-year high stood at $0.42 during Q2 2022, with a 5-year trough of -$1.9 in Q1 2021.
  • In the last 5 years, Barinthus Biotherapeutics' EPS (Basic) had a median value of -$0.43 in 2024 and averaged -$0.41.
  • Per our database at Business Quant, Barinthus Biotherapeutics' EPS (Basic) skyrocketed by 26923.08% in 2022 and then plummeted by 78571.43% in 2023.
  • Barinthus Biotherapeutics' EPS (Basic) (Quarter) stood at -$0.38 in 2021, then crashed by 49.52% to -$0.57 in 2022, then increased by 20.8% to -$0.45 in 2023, then decreased by 16.29% to -$0.52 in 2024, then skyrocketed by 31.21% to -$0.36 in 2025.
  • Its EPS (Basic) stands at -$0.36 for Q3 2025, versus -$0.52 for Q2 2025 and -$0.49 for Q1 2025.